A 12 Month, Multi-center, Open-label, Randomized, Controlled Study to Evaluate Efficacy/Safety and Evolution of Renal Function of Everolimus in Co-exposure With Tacrolimus in de Novo Liver Transplant Recipients.

Trial Profile

A 12 Month, Multi-center, Open-label, Randomized, Controlled Study to Evaluate Efficacy/Safety and Evolution of Renal Function of Everolimus in Co-exposure With Tacrolimus in de Novo Liver Transplant Recipients.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 24 May 2017

At a glance

  • Drugs Everolimus (Primary) ; Tacrolimus
  • Indications Liver transplant rejection
  • Focus Adverse reactions
  • Acronyms HEPHAISTOS
  • Sponsors Novartis
  • Most Recent Events

    • 05 Aug 2016 Planned End Date changed from 1 May 2017 to 1 Aug 2017.
    • 02 Aug 2016 Planned primary completion date changed from 1 May 2017 to 1 Aug 2017.
    • 16 Sep 2015 According to an abstract presented at the 17th Congress of the European Society for Organ Transplantation, 156 patients have been recruited till date.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top